Non-response to inclisiran therapy in three patients with statin intolerance: a case series
Anno:
2024
Background: Inclisiran is the first silencing-RNA therapy used to reduce LDL-C. It is also recommended in patients with statin intolerance. We describe a case series of three no-responder patients to inclisiran. Case series: 64-year-old man with medical history of type II diabetes mellitus, obesity, hypertension, chronic kidney disease (eGFR…